Halozyme Therapeutics, Inc. (HALO) Q3 2026 earnings results
Halozyme Therapeutics, Inc. (HALO) reported Q3 2026 results on Nov 5, 2026, 4:05:00 PM ET: adjusted EPS $2.39 vs. $2.36 expected (beat by 1.5%); revenue $493.00M vs. $491.56M expected (beat by 0.3%). Outlook: The company raised its full year 2026 guidance for total revenue to $1.860 billion - $1.925 billion and non-GAAP diluted EPS to $8.75 - $9.05.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $2.39 | $2.36 | Beat by 1.5% |
| Revenue | $493.00M | $491.56M | Beat by 0.3% |
Analyst estimate: the average forecast before the release.
Source
Figures from the press release, released Nov 5, 2026, 4:05:00 PM ET. Nexqual published them 3 min 0 s after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 39.2% from $354.26M.
Stock reaction
The results came out after the market closed. HALO closed at $103.63 on November 6, 2026, down 15.7% from its $122.96 close on November 5, 2026 before the results. Latest: $103.81 as of 11:40 AM ET, −15.6% since the pre-release close.
Questions and answers
Did Halozyme Therapeutics, Inc. beat earnings expectations?
Yes. Halozyme Therapeutics, Inc. reported adjusted EPS of $2.39 against an average analyst estimate of $2.36 (beat by 1.5%), and revenue of $493.00M against $491.56M expected (beat by 0.3%).
What were Halozyme Therapeutics, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $2.39 and revenue of $493.00M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 39.2% from $354.26M.
When did Halozyme Therapeutics, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:05:00 PM ET, in a company press release.
How did HALO stock react to the earnings?
The results came out after the market closed. HALO closed at $103.63 on November 6, 2026, down 15.7% from its $122.96 close on November 5, 2026 before the results. Latest: $103.81 as of 11:40 AM ET, −15.6% since the pre-release close.
What did Halozyme Therapeutics, Inc. say about its outlook?
The company raised its full year 2026 guidance for total revenue to $1.860 billion - $1.925 billion and non-GAAP diluted EPS to $8.75 - $9.05.
More on HALO
HALO stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: company earnings press release, Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt